increased use of spironolactone for heart failure is causing more hospitalizations and deaths
September 2004
The increased use of spironolactone for heart failure is causing more hospitalizations and deaths.
The problem started a few years ago when the "Randomized Aldactone Evaluation Study" (RALES) showed improved outcomes in patients with severe heart failure.
Since that study was published, lots of heart failure patients were put on spironolactone.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote